Analytical Data
-
Gene name
IFNL1
- Application
-
Alternative Names
IFNL1；IL29；ZCYTO21；Interferon lambda-1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8IU54
-
Expression Region
20-200aa
-
AA Sequence
GPVPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS SPVFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH TLHHILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV TFNLFRLLTR DLKYVADGNL CLRTSTHPES T
-
Molecular Weight
19.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IFNL1, also known as Interferon Lambda 1, is a member of the type III interferon family, which plays a crucial role in the immune response against viral infections. Its significance has gained attention due to its ability to modulate immune responses in various tissues, particularly in the liver and mucosal surfaces. IFNL1 exerts its effects through binding to the IFNLR1 receptor, activating signaling pathways that lead to the expression of antiviral genes and an enhancement of innate immunity. Research has shown that polymorphisms in the IFNL1 gene can influence susceptibility to viral infections, such as hepatitis C, and impact patient response to antiviral therapies. Furthermore, emerging studies are exploring the potential therapeutic applications of IFNL1 in treating a range of diseases, including viral infections, autoimmune disorders, and cancers. The understanding of IFNL1's biological functions and its role in the immune system has positioned it as a promising target for drug development, paving the way for new antiviral strategies and immunotherapies. As research progresses, the characterization of IFNL1 and its recombinant forms holds the potential to enhance our approach to managing infectious diseases and improving clinical outcomes in affected patients.
